Central Pharmaceutical JSC No3

Central Pharmaceutical JSC No3 maintains a strong liquidity position, as evidenced by a current ratio of 2.77, indicating that the company has more than double the current assets to cover its current liabilities. The company also reports a free cash flow of 30,372,410,520 VND, which suggests that it generates sufficient cash to fund operations and potentially reinvest in the business. The absence of long-term debt further supports the company's robust liquidity profile.

In terms of profitability, the company's return on equity (ROE) of 6.2% and return on assets (ROA) of 4.64% are in line with the industry's preferred metrics, which emphasize efficient use of equity and asset base to generate returns. The operating income of 35,390,696,460 VND and net income of 27,733,271,340 VND reflect a healthy margin structure, with gross profit of 68,111,769,630 VND supporting the company's profitability.

The company's revenue is primarily concentrated in its domestic market, with no disclosed international segments. This concentration may expose the company to local economic and regulatory risks, but it also allows for focused operations and potentially lower distribution costs. The company's capital expenditure of -803,465,680 VND indicates a net outflow, which may be related to maintenance or expansion of production facilities.

Looking ahead, the company is expected to maintain a stable growth trajectory, with no significant changes in revenue or profitability anticipated in the next fiscal year. The current fiscal year's revenue of 102,431,174,070 VND provides a baseline for future performance, and the company's strong liquidity and profitability suggest it is well-positioned to sustain operations and potentially expand.

The risk assessment indicates a low probability of liquidity or dilution issues, with no immediate filing-based flags detected. The company's debt-to-equity ratio of 0.0 further supports the low liquidity risk, as it is not leveraged and does not rely on external financing to fund operations. The absence of dilution risk is also a positive factor, as it suggests that the company is not issuing new shares to raise capital, which could otherwise dilute existing shareholders' equity.

Recent events, including analyst estimates, suggest a consensus price target of 63,500.00 VND, with no variation in the mean, median, high, or low price targets. This uniformity among analysts indicates a strong alignment in expectations for the company's future performance. No recent filings or transcripts have been disclosed that would suggest significant changes in the company's strategic direction or operational performance.

Net income grew 28.8% year-over-year to 156 billion VND, outpacing the 4.9% revenue growth rate.

Free cash flow surged 40.4% year-over-year to 95.7 billion VND, demonstrating strong cash generation capabilities.

Analysts project a 7.1% upside to a mean price target of 63,500 VND from the current market price.

The company maintains a zero debt-to-equity ratio, indicating a conservative capital structure with minimal leverage risk.

Revenue growth has decelerated to a 3.5% four-year CAGR, suggesting limited top-line expansion momentum.

Cash conversion ratio of 0.60 falls below the pharmaceutical cohort median of 0.95, indicating weaker cash efficiency.